| INTRODUC TI ON
Haemophilia is a rare bleeding disorder characterized by a congenital deficiency of factor VIII (haemophilia A) or factor IX (haemophilia B). The most common manifestation of haemophilia is bleeding into joints or soft tissues, either spontaneously or following trauma or invasive procedure. The management of haemophilia is hinged upon replacement therapy with plasma-derived or recombinant factor concentrates.
1 Haemophilia itself and its treatment are associated with burden of acute and chronic diseases, including, pain, difficulties of mobility, hepatitis B, C or HIV infection or chronic liver disease. 2 With the improvement in haemophilia treatment availability and safety, the life expectancy of people with haemophilia (PWH) has increased to 67-71 years. 3, 4 The ageing haemophilia patients are not spared by the conditions associated with ageing in the normal population, for example, obesity, osteopaenia, cardiovascular disease and cancer. 5, 6 Focusing on aspects critical for a test-retest experiment, haemophilia is a chronic disease, characterized by a progressive deterioration of joint functions which develops over many years which Outcomes, Burdens and Experiences (PROBE) Project was developed to directly access health status using outcomes PWH identified as important to their care. This questionnaire comprises two sections. The core section covers patient-reported outcomes, including general health problems and disease impact on the life experience of the participants. The detail of questionnaire development and pilot testing was described before by Skinner et al. 8 In brief, the development phase of the PROBE Project was conducted to develop and test the questionnaire for relevance, content, clarity and completeness. This phase enrolled 704 participants (PWH and individuals without a bleeding disorder). Most (>70%) of the participants completed the questionnaire within 15 minutes. In summary, the PROBE questionnaire comprises 29 items and 4 parts. Part I collects participants' demographic data, primary language of participants and time to complete the questionnaire; Part II, the PROBE PRO core is the core section collecting patient-reported outcomes (general health problems, including the presence of acute and chronic pain and the use of pain medication, limitations in mobility, the absence from work or school and health conditions), Part III collects haemophilia-related information, including severity of haemophilia, treatment regimes, number of bleeds, the presence of target joint (these two sections are not part of the tool, and data are collected only to help with result interpretation) and Part IV is the EuroQol 5-di- 
| Test-retest interval
We balanced the consideration of the recurrent nature of bleeding events with the need of avoiding easy recall of the answers given on the previous test. We selected a short primary test-retest interval (one day), to minimize the chance of background noise introduced by the occurrence of any bleeds. However, we also included a third repeat after a 4-to 6-week interval, to minimize recall. The first and second repeats were done on paper and the third using a web-based version. Since the intended use of the PROBE is to interchangeably use the paper or online version, we decided to simplify the study and accept not discriminating the variability linked to use of the paper or online version of the questionnaire.
| Study procedure
Sets of adhesive labels with alpha-numeric codes were used to pair up replicates, avoiding use of any subject identifier. Identical and non-identifiable envelopes were prepared, each containing four copies of a sticky label with the same 6-digit code and a paper card with the PROBE website address. On time 1 (T1), each participant received an envelope, was invited to apply one of the stickers on the card, wrote his/her name on the paper card (in case the envelope was lost) and was asked to keep the envelope with them for the entire meeting and to take it home. Each participant was asked to fill out a paper copy of the PROBE questionnaire and stick one label on it. On time 2 (T2), they did the same and attached a second label. For time 3 (T3), participants were instructed to log into the PROBE website, using the same 6-digit code, and complete the questionnaire.
T3 web-based responses were collected over 50 days beginning one week after T1. Participants were asked to fill out the questionnaire objectively, answering the questions for themselves. The questionnaires were collected immediately after being filled out on T1 and T2, so that participants could not access the questionnaire filled the previous days. Participants were allowed to select either an English or Spanish version of the PROBE tool. As a sensitivity analysis, participants were stratified into PWH and participants without a bleeding disorder.
| Calculation of the PROBE score

| Statistical analysis
The sample size for the test-retest study is defined, when the measurement properties of the instrument under study are known, by calculating the number of subjects needed to exclude a prespeci- 
| RE SULTS
A total of 63 participants were enrolled in this study. Median age was 50 (range: 17-76) years. Thirty (47.6%) were PWH, and 33 (52.5%)
were participants without a bleeding disorder. Forty-five participants (71.4%) were male. Table 1 shows participant demographic data and clinical characteristics. Table 2 demonstrates test-retest reliability of this domain. For T1 vs T2, Kappa coefficients ranged from 0.69 to 1.00. Five items were almost in perfect agreement, whereas four items showed substantial agreement.
| Patient-reported outcomes-general health problems (Part II)
The lowest Kappa coefficients were found in the item measuring "acute pain" (κ = 0.69). Percentage agreement ranged from 85% to 98% indicating almost perfect agreement for all items.
Kappa coefficients for the web-based vs paper-based questionnaire ranged from 0.30 to 0.92, and percentage agreement ranged from 65% to 95%. Kappa indicated moderate to substantial agreement for all except one item (acute pain). However, percentage agreement indicated substantial agreement and almost perfect agreement for all items.
| Haemophilia-related problems (Part III)
Only PWH completed this part. Table 3 demonstrates test-retest reliability for haemophilia-related problems. Kappa coefficients ranged from 0.50 to 1.0, and percentage agreement ranged from 87% to 100%.
All but one of the items were in almost perfect agreement. Of these, 5 out of 11 items were in perfect agreement (κ = 1.0). Percentage agreement indicated almost perfect agreement for all items.
Test-retest reliability of the web-based questionnaire compared with the paper-based version had Kappa coefficients of 0.57 to 1.0 and percentage agreement of 80% to 100%. All but one of the items (item 20-bleed within the past 2 weeks) were in substantial to perfect agreement.
| Health-related quality of life (Part IV)
HRQOL was evaluated in both PWH and participants without a bleeding disorder. Table 4 
| Total PROBE score
| Secondary analysis and sensitivity analysis
| D ISCUSS I ON
This study investigated the test-retest reliability of the PROBE questionnaire in PWH, administered on paper over two consecutive days and subsequently via a dedicated web-based version. The results demonstrate an excellent overall agreement.
The PROBE tool incorporates EQ-5D-5L, which has been widely translated and validated in multinational studies 9, 27 and is broadly surprising, considering the specific transient nature of acute pain in most of the cases. Possibly, the time interval to assess test-retest properties for acute pain should be measured in hours if not minutes. Therefore, this finding reflected the nature of the item determining acute pain which was more vulnerable to change during the study period when compared to the others. If yes, do you currently have a clinically significant inhibitor?
1.00 (1.00-1.00) 100.0 (100.0-100.0) 1.00 (1.00-1.00) 100.0 (100.0-100.0) 
10
Have you had three or more spontaneous bleeds (including those resulting from normal daily activity) into any one joint in the past 6 mo?
1.00 (1.00-1.00) 100.0 (100.0-100.0) 1.00 (1.00-1.00) 100.0 (100.0-100.0)
11
Is the range of motion of any joint currently reduced because of your having haemophilia?
1.00 (1.00-1.00) 100.0 (100.0-100.0) 1.00 (1.00-1.00) 100.0 (100.0-100.0) preferentially one of the answers over the others. For this circumstance, low Kappa coefficients may not refer to low rate of agreement and should be disregarded.
An objective of this study was to assess the test-retest characteristics of the PROBE when data are obtained with the paper and web-based versions of the questionnaire. We did not include a randomization of the order of administration of the two forms of the questionnaire for practical reasons. Therefore, we cannot discriminate whether the slightly lower agreement observed when comparing the web-based questionnaire (T3) with the paper version (T1) is due to the modality or the lag time. Indeed, the difference could be entirely explained by the elapsed time between the two replicas of the test rather than the platform of the tests. However, the observed difference is more of scientific than practical interest: the results of our Average of PROBE score T1 and PROBE score T2 study suggest that the web-based PROBE questionnaire may be used in as an alternative to the paper-based questionnaire.
There are some limitations in this study that need to be addressed.
First, the participant selection was based on a convenience sample of participants in a specific haemophilia-related workshop. These participants may be more knowledgeable about their health status than those who did not attend the workshops, limiting generalizability to patients within the broader haemophilia community. Second, the participants were reminded to submit their response via web-based questionnaire beginning 1 month after the workshop. The differences in the time interval from T1 to completion of the web survey T3 (up to 8 weeks) may contribute to the variance of agreement in our study.
Third, 8 and 23 participants failed to return the questionnaire at T2
and T3 of the study, respectively. We performed the analysis based on complete case analysis. Therefore, the test-retest analysis may lead to overestimating the agreement reliability, even if with a low margin.
Fourth, although we enrolled participants from multiple countries, most of them are from North America and Europe. The results of this study may not reflect the broad spectrum of patients with differing haemophilia care. Finally, we have not yet developed a definitive summary PROBE score; specifically, we plan to further explore how to optimally differentiate the impact of acute bleed and chronic arthropathy on pain and function; however, the provisional summary score we have tested performed already more than satisfactorily and allow to consistently obtain different scores in patients and controls.
| CON CLUS ION
The PROBE tool is designed to be used for assessing the health status of PWH, comparing cross-sectionally among different settings, longitudinally over time and across changes in care availability and modality of provision and comparing people with haemophilia with a reference population. The test-retest properties reported in this study support PROBE's use, both as a paper-based and web-based questionnaire.
Additional studies are planned to investigate the test-retest properties of the PROBE questionnaire across random samples of people from different countries and to test the discrimination and responsiveness of the tool.
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